Regeneron Pharmaceuticals (REGN) – Analysts’ Recent Ratings Updates

A number of research firms have changed their ratings and price targets for Regeneron Pharmaceuticals (NASDAQ: REGN):

• 5/19/2026 – Regeneron Pharmaceuticals had its price target lowered by Canaccord Genuity Group Inc. from $1,057.00 to $875.00. They now have a “buy” rating on the stock.
• 5/18/2026 – Regeneron Pharmaceuticals had its price target lowered by BMO Capital Markets from $900.00 to $730.00. They now have an “outperform” rating on the stock.
• 5/18/2026 – Regeneron Pharmaceuticals had its price target lowered by Truist Financial Corporation from $796.00 to $778.00. They now have a “buy” rating on the stock.
• 5/18/2026 – Regeneron Pharmaceuticals had its price target lowered by JPMorgan Chase & Co. from $950.00 to $850.00. They now have an “overweight” rating on the stock.
• 5/18/2026 – Regeneron Pharmaceuticals had its price target lowered by Royal Bank Of Canada from $762.00 to $707.00. They now have a “sector perform” rating on the stock.
• 5/18/2026 – Regeneron Pharmaceuticals had its price target lowered by Wells Fargo & Company from $800.00 to $700.00. They now have an “equal weight” rating on the stock.
• 5/18/2026 – Regeneron Pharmaceuticals had its price target lowered by Piper Sandler from $875.00 to $855.00. They now have an “overweight” rating on the stock.
• 5/18/2026 – Regeneron Pharmaceuticals was downgraded by Citigroup Inc. from “buy” to “neutral”. They now have a $700.00 price target on the stock, down from $900.00.
• 5/18/2026 – Regeneron Pharmaceuticals had its “market perform” rating reaffirmed by Leerink Partners. They now have a $641.00 price target on the stock, down from $792.00.
• 5/2/2026 – Regeneron Pharmaceuticals was upgraded by Wall Street Zen from “hold” to “buy”.
• 5/1/2026 – Regeneron Pharmaceuticals had its price target raised by Guggenheim from $975.00 to $995.00. They now have a “buy” rating on the stock.
• 4/30/2026 – Regeneron Pharmaceuticals had its price target lowered by Royal Bank Of Canada from $779.00 to $762.00. They now have a “sector perform” rating on the stock.
• 4/30/2026 – Regeneron Pharmaceuticals had its price target lowered by Barclays PLC from $923.00 to $917.00. They now have an “overweight” rating on the stock.
• 4/30/2026 – Regeneron Pharmaceuticals had its price target lowered by Truist Financial Corporation from $801.00 to $796.00. They now have a “buy” rating on the stock.
• 4/30/2026 – Regeneron Pharmaceuticals had its price target lowered by Wells Fargo & Company from $825.00 to $800.00. They now have an “equal weight” rating on the stock.
• 4/23/2026 – Regeneron Pharmaceuticals had its price target raised by TD Cowen from $880.00 to $960.00. They now have a “buy” rating on the stock.
• 4/23/2026 – Regeneron Pharmaceuticals had its “overweight” rating reaffirmed by Cantor Fitzgerald. They now have a $800.00 price target on the stock.
• 4/11/2026 – Regeneron Pharmaceuticals was downgraded by Wall Street Zen from “buy” to “hold”.
• 4/10/2026 – Regeneron Pharmaceuticals had its price target raised by Morgan Stanley from $769.00 to $796.00. They now have an “equal weight” rating on the stock.
• 4/8/2026 – Regeneron Pharmaceuticals had its price target lowered by Sanford C. Bernstein from $925.00 to $921.00. They now have an “outperform” rating on the stock.
• 3/31/2026 – Regeneron Pharmaceuticals had its price target lowered by Truist Financial Corporation from $818.00 to $801.00. They now have a “buy” rating on the stock.
• 3/31/2026 – Regeneron Pharmaceuticals is now covered by Piper Sandler. They set an “overweight” rating and a $875.00 price target on the stock.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th will be issued a $0.94 dividend. The ex-dividend date is Wednesday, May 20th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.6%. Regeneron Pharmaceuticals’s payout ratio is 9.16%.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $705.24, for a total value of $70,524.00. Following the sale, the director directly owned 17,503 shares in the company, valued at $12,343,815.72. The trade was a 0.57% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.